Sanofi Dirección

Dirección controles de criterios 3/4

El CEO de Sanofi's es Paul Hudson , nombrado en Sep 2019, tiene una permanencia de 4.58 años. compensación anual total es €10.72M, compuesta por 13.1% salario y 86.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.006% de las acciones de la empresa, por valor de €6.24M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 4.8 años, respectivamente.

Información clave

Paul Hudson

Chief Executive Officer (CEO)

€10.7m

Compensación total

Porcentaje del salario del CEO	13.1%
Permanencia del CEO	4.7yrs
Participación del CEO	0.006%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Hudson en comparación con los beneficios de Sanofi?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	n/a	n/a	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Compensación vs. Mercado: La compensación total de Paul($USD11.42M) está por encima de la media de empresas de tamaño similar en el mercado Italian ($USD3.90M).

Compensación vs. Ingresos: La compensación de Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Paul Hudson (56 yo)

4.7yrs

Permanencia

€10,718,747

Compensación

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hudson	CEO & Director	4.7yrs	€10.72m	0.0057% € 6.6m
François-Xavier Roger	Executive VP & CFO	less than a year	sin datos	sin datos
Madeleine Roach	Executive VP & Head of Business Operations	less than a year	sin datos	sin datos
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	sin datos	sin datos
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	sin datos	sin datos
Eva Schaefer-Jansen	Head of Investor Relations	no data	sin datos	sin datos
Dante Beccaria	Global Compliance Officer & VP	12.1yrs	sin datos	sin datos
Roy Papatheodorou	Executive VP & General Counsel	2.3yrs	sin datos	sin datos
Josep Catlla	Head of Communications	no data	sin datos	sin datos
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	19.8yrs	sin datos	sin datos
Natalie Bickford	Executive VP & Chief People Officer	3.8yrs	sin datos	sin datos
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22yrs	sin datos	sin datos

4.2yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1SAN se considera experimentado (4.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hudson	CEO & Director	4.6yrs	€10.72m	0.0057% € 6.6m
Jean-François Dehecq	Honorary Chairman	14yrs	€4.71m	sin datos
Serge Weinberg	Honorary Chairman	less than a year	€324.96k	0.00013% € 151.1k
Patrick Kron	Independent Director	10yrs	€175.75k	0.000080% € 93.0k
Lise Kingo	Independent Director	4.1yrs	€148.25k	0.000080% € 93.0k
Frederic Oudea	Independent Chairman	less than a year	€573.52k	0.000080% € 93.0k
Fabienne Lecorvaisier	Independent Director	11yrs	€156.50k	0.000080% € 93.0k
Gilles Schnepp	Independent Director	2.4yrs	€175.75k	0.000080% € 93.0k
Diane Souza	Independent Director	8yrs	€217.00k	0.00010% € 116.2k
Thomas Sudhof	Independent Director	8yrs	€222.50k	0.00010% € 116.2k
Rachel Duan	Independent Director	4.1yrs	€145.50k	0.000080% € 93.0k
Christophe Babule	Director	5.3yrs	€134.50k	0.000080% € 93.0k

4.9yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1SAN se considera experimentada (4.8 años de antigüedad promedio).

Sanofi Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Sanofi Announces Board and Committee Appointments

Sanofi Announces CFO Changes, Effective April 1, 2024

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Recent updates

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings released: EPS: €0.91 (vs €1.60 in 1Q 2023)

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings released: EPS: €4.31 (vs €6.69 in FY 2022)

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings released: EPS: €4.31 (vs €6.69 in FY 2022)

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Third quarter 2023 earnings released: EPS: €2.02 (vs €1.66 in 3Q 2022)

Sanofi Reiterates Earnings Guidance for the Year 2023

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Second quarter 2023 earnings released: EPS: €1.15 (vs €0.94 in 2Q 2022)

Sanofi Provides Earnings Guidance for the Year 2023

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad